The global bronchodilator market size is projected to expand from USD 38.2 billion in 2024 to USD 67.8 billion by 2034. Sales of bronchodilators are predicted to soar at a CAGR of 5.9% in the estimated period 2024 to 2034. In 2023, the bronchodilator market value totaled USD 36.2 billion and is set to exhibit a y-o-y growth of 5.7% in 2024.
| Attributes | Key Insights |
|---|---|
| Bronchodilator Market Value in 2023 | USD 36.2 billion |
| Estimated Bronchodilator Market Size (2024) | USD 38.2 billion |
| Projected Bronchodilator Market Revenue (2034) | USD 67.8 billion |
| Expected Bronchodilator Market CAGR (2024 to 2034) | 5.9% |
| Market Share of Top 5 Countries | 46.9% |
Bronchodilator Market Overview
Bronchodilators have become highly sought-after medications to treat different respiratory diseases and other medical conditions. This class of drugs is set to aid in relaxing the airway-restricting muscles.
Bronchodilators are expected to be extensively used to reduce pulmonary mucus. Patients with respiratory disorders are recommended to use inhalers or nebulizers to administer these drugs.
Bronchodilators used for inhalation also affect mucociliary clearance. They are set to be used in the treatment of obstructive lung disorders (bronchi), such as asthma, and chronic obstructive pulmonary disorders (COPD) by loosening the muscles in the lungs and widening the airways. Hence, the growing prevalence of these diseases will likely drive demand for bronchodilators.
Short-acting and long-acting bronchodilators are the two types of bronchodilators used by patients suffering from respiratory disease. To treat respiratory conditions, bronchodilators come in a range of forms, including sympathomimetic, anticholinergic, phosphodiesterase inhibitors, and combination drugs. Depending on the method of administration, these types are available in different forms, such as inhalers, tablets, liquids, and injectables.
Other factors influencing market growth include:
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
As per the latest bronchodilator industry analysis, global bronchodilator sales grew at a CAGR of 5.0% between 2019 and 2023. The market value for bronchodilators was about 43.3% of the respiratory diseases drug market in 2022, which was valued at USD 79.8 billion.
| Historical CAGR (2019 to 2023) | 5.0% |
|---|---|
| Forecast CAGR (2024 to 2034) | 5.9% |
The main factor propelling the growth of the bronchodilator industry is the rising prevalence of respiratory illnesses, including asthma and chronic obstructive pulmonary disease (COPD), worldwide. Similarly, rising disposable income, a growing geriatric population, and a rise in public awareness of healthcare are all predicted to spur market expansion.
The market is also growing as a result of increased bronchodilator use in the treatment of cystic fibrosis. Subsequently, favorable government initiatives to reduce the burden of respiratory diseases are set to elevate demand for bronchodilators through 2034.
In recent years, there has been a spike in respiratory illnesses such as asthma. For instance, as per the Centers for Disease Control and Prevention (CDC), 1 in 13 individuals have asthma, which results in 9.8 million doctor visits, 188,968 hospital inpatient discharges, and 1.8 million trips to emergency rooms annually.
Over 25 million people in the United States, or 7.7% of adults and 8.4% of children, suffer from asthma, making it a common condition globally. With 8% of the adult population and 12% to 13% of children estimated to have asthma, the United Arab Emirates has a higher reported prevalence of the disease than the United States.
To treat asthma and relieve its symptoms, bronchodilators are set to be frequently used. Hence, the growing prevalence of asthma will play a key role in bolstering sales of bronchodilators.
The market for bronchodilators is expected to see new prospects due to continuous research and development efforts. New drug administration methods are being developed by manufacturers, which is anticipated to increase drug consumption and fuel the global bronchodilator market.
Top bronchodilator manufacturers are investing significantly in developing multiple nebulizer and inhaler types that would give patients convenient access. The development of novel bronchodilators with higher effectiveness and minimal side effects will boost the target market.
Improvements in healthcare structures and increasing government initiatives are expected to boost the market for bronchodilators globally. These factors will create lucrative growth opportunities for bronchodilator manufacturing companies.
Governments worldwide are launching different schemes to reduce the burden of respiratory diseases. Several steps are also taken to make the treatments affordable for everyone and spread awareness about the prevention of diseases. This is predicted to positively impact bronchodilator sales.
The growing incidence of COPD is acting as a catalyst fueling demand for bronchodilators, and the trend is expected to continue through 2034. Subsequently, the introduction of new programs to tackle the COPD burden will likely foster the growth of the bronchodilator industry.
Countries worldwide are launching new programs and initiatives to counter the burden of respiratory diseases. For instance, the COPD National Action Plan was recently launched to reduce COPD burden.
The COPD action plan aims to enhance the prevention, diagnosis, treatment, and management of COPD by enhancing the quality of care provided throughout the healthcare continuum. It strives to help those with COPD, their family members, and their caregivers.
Principal Consultant
Bronchodilators play an important role in terms of loosening up the muscles that constrict the airways. However, the side effects associated with bronchodilators are the main hindrance to the growth of this market.
Beta-2 agonists such as salbutamol and anticholinergics have several common adverse effects. These include trembling, especially in the hands, nervous tension, headaches, muscular cramps, dry mouth, constipation, difficulty in swallowing (dysphagia), heartburn, and palpitations.
When using an inhaler or nebulizer, patients can aggravate their glaucoma if the anticholinergic medicine gets in their eyes. If theophylline builds up in a patient’s body in excess, it can have negative side effects.
Theophylline side effects are more likely to affect older persons since their livers can be less able to eliminate it from their systems. A quick heartbeat (tachycardia), an irregular heartbeat (arrhythmia), headaches, and difficulty sleeping are a handful of theophylline's negative effects. These factors are expected to limit the growth of the bronchodilator market.
The table below shows the anticipated growth rates of the top countries. The United States, India, and China are expected to record lucrative CAGRs of 6.1%, 6.2%, and 5.3%, respectively, through 2034.
| Countries | CAGR (2023 to 2034) |
|---|---|
| United States | 6.1% |
| Canada | 5.0% |
| China | 5.3% |
| India | 6.2% |
| Germany | 5.1% |
The United States bronchodilator market value totaled USD 9.39 billion in 2023. It accounted for about 25.9% share of the global bronchodilator industry in 2023. Over the forecast period, sales of bronchodilators in the United States are predicted to rise at a 6.1% CAGR.
As per the latest report, the United States is expected to experience significant growth throughout the forecast period. This is attributable to the rising prevalence of COPD and other respiratory diseases, the high demand for breathing disorder medications, and the growing popularity of inhaled bronchodilators.
The increasing prevalence of COPD and asthma is playing a vital role in bolstering sales of bronchodilators in the United States. As per the Centers for Disease Control and Prevention (CDC), chronic lower respiratory disease remained the fourth most common cause of death in the United States in 2021.
More than 15 million people have COPD, and over 150,000 of them die from it each year, or one every four minutes. This is prompting patients suffering from COPD to opt for COPD treatment drugs, including bronchodilators.
Bronchodilators are mainly used as medication for COPD and asthma. They help relax the muscles in the airways and open them up, making breathing easier for patients with asthma and COPD. This is a prime driver boosting the growth of the bronchodilator market in the country.
Germany is set to exhibit a CAGR of 5.1% during the assessment period. It held a value share of about 4.0% in the global bronchodilator industry in 2023. The good healthcare infrastructure and increased awareness among people about hygiene are driving the growth of the bronchodilator market in Germany.
According to the World Health Organization (WHO), Germany is a top global leader in public health, as seen by its global health strategy and programs and the experience, knowledge, and funding it offers to WHO. Due to these reasons, the market for bronchodilators in Germany is increasing.
Growing preference for long-acting bronchodilators is another key factor expected to boost sales in the country. Similarly, rising cases of asthma will improve Germany’s bronchodilator industry share through 2034.
India held a 4.3% share of the worldwide bronchodilator industry in 2023. Over the assessment period, demand for bronchodilators in the country is anticipated to increase at a CAGR of 6.2%.
The increasing burden of non-communicable diseases and government initiatives toward the healthcare sector is expected to drive the growth of the bronchodilator market in India. The government is launching different initiatives and programs to reduce the burden of respiratory diseases.
For instance, in February 2017, the honorable Health and Family Welfare Minister launched the Kerala COPD Prevention and Control Program- ‘SWAAS.’ It is the country's first COPD prevention and control program that can help to tackle the burden of COPD. Such initiatives are creating a favorable environment for the expansion of the bronchodilator market.
Canada’s bronchodilator market size reached over USD 1.6 billion at the end of 2023. For the assessment period, bronchodilator sales in the country are projected to soar at a 5.0% CAGR, making it a lucrative market for companies.
Multiple factors are expected to stimulate growth in Canada’s bronchodilator industry. These include rising incidence of respiratory diseases, favorable government support, and growing adoption of combination therapies.
The cases of respiratory diseases like COPD and asthma are rising dramatically across Canada. This is expected to elevate the demand for bronchodilators as they are often used to treat these respiratory diseases.
China is emerging as a highly lucrative market for bronchodilators across East Asia. This is attributable to factors such as the rising cases of COPD and asthma, increasing awareness about bronchodilators, and the rising popularity of home healthcare.
China’s bronchodilator market size reached USD 2.94 billion in 2023. Demand for bronchodilators in China is predicted to surge at a steady CAGR of 5.3% throughout the forecast period.
Bronchodilators and other airway expansion medications are becoming highly popular among patients and healthcare professionals in China, leading to increased demand for these medications. This is due to the rising awareness about the benefits of these bronchodilators.
Several public health campaigns are being launched in China to educate people about respiratory diseases and their treatment approaches. This is expected to uplift demand for bronchodilators and other related medications, thereby fostering China’s bronchodilator market growth.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The section below shows the phosphodiesterase inhibitor segment dominating the bronchodilator market. It is poised to exhibit a CAGR of 6.2% during the forecast period. By application, the asthma segment is expected to thrive at a 6.6% CAGR.
Based on the route of administration, the oral segment is expected to lead the global bronchodilator industry. It will likely expand at a 6.4% CAGR between 2024 and 2034. By distribution channel, the retail pharmacies segment is anticipated to thrive at a CAGR of 6.0% through 2034.
Market Growth Outlook by Drug Class
| Drug Class | Value CAGR |
|---|---|
| Sympathomimetic | 6.7% |
| Anticholinergics | 5.3% |
| Phosphodiesterase Inhibitor | 6.2% |
| Combination Drugs | 4.9% |
| Others | 5.9% |
Based on drug class, the phosphodiesterase inhibitor segment dominated the global bronchodilator market with a revenue share of 25.6% in 2023. Over the forecast period, demand for phosphodiesterase inhibitors is projected to rise at a CAGR of around 6.2%.
Phosphodiesterase inhibitors have become highly sought-after drugs to treat a variety of respiratory disorders. For instance, they are effective in treating asthma and chronic obstructive pulmonary disease (COPD).
Phosphodiesterase inhibitors work by curbing the breakdown of cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate (cAMP). These molecules are essential for the relaxation of smooth muscles, thereby helping to open up airways and making it easier to breathe.
The growing adoption of phosphodiesterase inhibitors to treat several respiratory diseases is expected to boost the target segment. Key bronchodilator companies are expected to capitalize on this rising demand by releasing new phosphodiesterase inhibitors.
Sympathomimetic drugs, on the other hand, are expected to witness a higher demand in the global market. This is due to their ability to treat different respiratory diseases by mimicking the effects of the sympathetic nervous system. The target segment is set to thrive at a 6.7% CAGR through 2034.
Market Growth Outlook by Application
| Application | Value CAGR |
|---|---|
| Asthma | 6.6% |
| COPD | 5.9% |
| Others | 5.2 |
As per the latest bronchodilator market analysis, asthma is predicted to remain a key revenue-generation segment for manufacturers of bronchodilators. This is due to the rising prevalence of asthma and the growing need for asthma relief medications.
In 2023, the asthma segment accounted for a revenue share of 34.2%. Over the forecast period, the target segment is poised to exhibit a CAGR of 6.6%, owing to the rising prevalence of pediatric asthma cases.
In recent years, there has been a spike in asthma cases worldwide. As per the World Health Organization (WHO), around 262 million people were affected by asthma in 2019, while there were 455000 asthma-related deaths. This is expected to drive the demand for bronchodilators as they relieve asthma symptoms and allow people with asthma to lead a normal life.
Market Growth Outlook by Route of Administration
| Route of Administration | Value CAGR |
|---|---|
| Oral | 6.4% |
| Injection | 5.7% |
| Inhalation | 5.1% |
Orally used bronchodilators held a prominent market share value of 46.5% in 2023 and are expected to rise with a CAGR of 6.4% during the forecast period. This is attributable to the convenience and cost-effectiveness of the orally administered bronchodilators.
Oral bronchodilators remain the preferable route of drug administration owing to their better convenience and inexpensive nature. They tend to be more readily accepted by patients, which promotes greater adherence to prescribed treatment regimens, eventually leading to improved health outcomes.
Market Growth Outlook by Distribution Channel
| Distribution Channel | Value CAGR |
|---|---|
| Retail Pharmacies | 6.0% |
| Hospital Pharmacies | 5.3% |
| E-Commerce | 6.4% |
| Drug Stores | 6.1% |
The retail pharmacies segment accounted for a dominant market share value of 32.4% at the end of 2023. For the projection period, the target segment is anticipated to thrive at a CAGR of 6.0%. This is due to the easy availability of bronchodilators in retail pharmacies.
Retail pharmacies provide a diverse selection of bronchodilators with heavy discounts. As a result, they are becoming an ideal destination for people to purchase bronchodilators. Hence, the growing inclination of patients toward purchasing bronchodilators from retail pharmacies will boost the target segment.
The bronchodilator industry is highly fragmented, with several companies competing for market share. Top manufacturers of bronchodilators are focusing on launching new products to match consumer demand and increase their client base. They are also using strategies such as mergers, acquisitions, partnerships and collaborations, and celebrity endorsements to stay ahead of the competition.
Recent Developments in the Bronchodilator Market
The global bronchodilator market value totaled USD 36.2 billion in 2023.
The bronchodilator market size is expected to reach USD 38.2 billion in 2024.
By 2034, the global bronchodilator market value is projected to reach USD 67.8 billion.
Demand for bronchodilators is predicted to rise at a 5.9% CAGR through 2034.
High prevalence of lung diseases such as COPD & asthma and new product launches.
North America dominated the global market with a share of 27.5% in 2023.
Sales in Germany are set to expand at a 5.1% CAGR through 2034.
The United States, China, India, Germany, and the United Kingdom.
Abbott Laboratories, AstraZeneca plc., and Boehringer Ingelheim International GmbH.
From 2019 to 2023, the market for bronchodilators expanded at 5.0% CAGR.
India's bronchodilator market is expected to total USD 1.5 billion by 2034.
Bronchodilator demand in China is projected to surge at 5.3% CAGR through 2034.
Cholinergic and adrenergic receptors are the main targets of bronchodilators.
Anticholinergics and sympathomimetic drugs are used as bronchodilators.
Anticholinergics, Theophylline, and beta 2-agonists.
1. Executive Summary 2. Market Overview 3. Brand Mapping Analysis 4. Distribution Channel Wise Key Brand Positioning 5. Consumer Buying Behavior Analysis 6. Market Trends & Dynamics 7. Value Added Insights 8. Market Background 9. Global Market Demand Analysis 2019 to 2023 and Forecast, 2024 to 2034 10. Global Market - Pricing Analysis 11. Global Market Demand (in Value or Size in USD billion) Analysis 2019 to 2023 and Forecast, 2024 to 2034 12. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Drug Class 12.1. Sympathomimetic 12.2. Anticholinergics 12.3. Phosphodiesterase Inhibitor 12.4. Combination Drugs 12.5. Others 13. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Application 13.1. Asthma 13.2. COPD 13.3. Others 14. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Route of Administration 14.1. Oral 14.2. Injection 14.3. Inhalation 15. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel 15.1. Retail Pharmacies 15.2. Hospital Pharmacies 15.3. E-commerce 15.4. Drug Stores 16. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Region 16.1. North America 16.2. Latin America 16.3. Europe 16.4. South Asia 16.5. East Asia 16.6. Oceania 16.7. Middle East & Africa 17. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034 18. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034 19. Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034 20. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034 21. South Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034 22. Oceania Market Analysis 2019 to 2023 and Forecast 2024 to 2034 23. Middle East & Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034 24. Market Structure Analysis 25. Competition Analysis 25.1. Abbott Laboratories Overview 25.2. AstraZeneca plc. 25.3. Boehringer Ingelheim International GmbH 25.4. GlaxoSmithKline Plc. 25.5. F. Hoffmann-La Roche Ltd. 25.6. Novartis AG. 25.7. Pfizer Inc. 25.8. SANOFI 25.9. Teva Pharmaceutical Industries Ltd. 25.10. Vectura Group Plc. 25.11. Sunovion Pharmaceuticals Inc 25.12. Aerogen Pharma Ltd 25.13. Aurobindo Pharma Ltd. 25.14. Cipla Ltd. 26. Assumptions and Acronyms Used 27. Research Methodology
Explore Healthcare Insights
View Reports
Bronchodilator Market
